{"id":740626,"date":"2023-03-16T07:33:56","date_gmt":"2023-03-16T11:33:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/"},"modified":"2023-03-16T07:33:56","modified_gmt":"2023-03-16T11:33:56","slug":"update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/","title":{"rendered":"UPDATE — Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023"},"content":{"rendered":"
\n

WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced\u00a0the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.<\/p>\n

Details for the abstract and poster presentation are as follows:<\/p>\n

\n
\n Abstract Number: <\/strong>
\n 1829<\/strong>
\n <\/a>\n <\/p>\n

\n Title:<\/u>\u00a0Generation of IL-21 INDUKINE\u2122 molecules for the treatment of cancer
Session Category:<\/u> Immunology
Session Title:<\/u> Immunomodulatory Agents and Interventions 2
Session Date and Time:<\/u> Monday, April 17, 2023 from 9:00 a.m. – 12:30 p.m.
Location:<\/u> Poster Section 24
Poster Board Number:<\/u> 1<\/p>\n

\n
\n
\n Abstract Number:\u00a0CT133<\/u>
\n <\/strong>
\n <\/a>\n <\/p>\n

\n Title:<\/u>\u00a0Trial in progress: a multicenter phase 1\/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors
Session Title:<\/u>\u00a0Phase I Clinical Trials in Progress
Session Date and Time:<\/u>\u00a0Monday, April 17, 2023 from 1:30\u00a0p.m. – 5:00\u00a0p.m.
Location:<\/u>\u00a0Poster Section 46
Poster Board Number:<\/u>\u00a021<\/p>\n

\n
\n
\n Abstract Presentation Number:\u00a0CT254<\/u>
\n <\/strong>
\n <\/a>\n <\/p>\n

\n Title:<\/u>\u00a0Trial in progress: a first-in-human, phase 1, multicenter dose escalation and dose expansion study of WTX-330 in adult patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma
Session Title:<\/u>\u00a0Phase I and First-in-Human Clinical Trials in Progress
Session Date and Time:<\/u>\u00a0Tuesday, April 18, 2023 from 1:30\u00a0p.m. – 5:00\u00a0p.m.
Location<\/u>:\u00a0Poster Section 46
Poster Board Number:<\/u>\u00a017<\/p>\n

\n About Werewolf Therapeutics<\/strong>
\n
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR\u2122 platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE\u2122 molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com<\/a>.<\/p>\n

\n Investor Contact:<\/strong>
\n \n <\/p>\n

Josh Rappaport
Stern IR
212.362.1200
Josh.Rappaport@sternir.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
Peg Rusconi
VERGE Scientific Communications
prusconi@vergescientific.com<\/a><\/p>\n

\n Company Contact:<\/strong>
\n
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced\u00a0the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida. Details for the abstract and poster presentation are as follows: Abstract Number: 1829 Title:\u00a0Generation of IL-21 INDUKINE\u2122 molecules for the treatment of cancerSession Category: ImmunologySession Title: Immunomodulatory Agents and Interventions 2Session Date and Time: Monday, April 17, 2023 from 9:00 a.m. – 12:30 p.m.Location: Poster Section 24Poster Board Number: 1 Abstract Number:\u00a0CT133 Title:\u00a0Trial … <\/p>\n

Continue reading “UPDATE — Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740626","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nUPDATE - Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UPDATE - Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced\u00a0the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida. Details for the abstract and poster presentation are as follows: Abstract Number: 1829 Title:\u00a0Generation of IL-21 INDUKINE\u2122 molecules for the treatment of cancerSession Category: ImmunologySession Title: Immunomodulatory Agents and Interventions 2Session Date and Time: Monday, April 17, 2023 from 9:00 a.m. – 12:30 p.m.Location: Poster Section 24Poster Board Number: 1 Abstract Number:\u00a0CT133 Title:\u00a0Trial … Continue reading "UPDATE — Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-16T11:33:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTUxMiM1NDY1MjMxIzIyMDc3NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"UPDATE — Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023\",\"datePublished\":\"2023-03-16T11:33:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\\\/\"},\"wordCount\":422,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4OTUxMiM1NDY1MjMxIzIyMDc3NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\\\/\",\"name\":\"UPDATE - Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4OTUxMiM1NDY1MjMxIzIyMDc3NDc=\",\"datePublished\":\"2023-03-16T11:33:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4OTUxMiM1NDY1MjMxIzIyMDc3NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4OTUxMiM1NDY1MjMxIzIyMDc3NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UPDATE — Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"UPDATE - Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/","og_locale":"en_US","og_type":"article","og_title":"UPDATE - Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023 - Market Newsdesk","og_description":"WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the \u201cCompany\u201d or \u201cWerewolf\u201d) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body\u2019s immune system for the treatment of cancer, today announced\u00a0the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida. Details for the abstract and poster presentation are as follows: Abstract Number: 1829 Title:\u00a0Generation of IL-21 INDUKINE\u2122 molecules for the treatment of cancerSession Category: ImmunologySession Title: Immunomodulatory Agents and Interventions 2Session Date and Time: Monday, April 17, 2023 from 9:00 a.m. – 12:30 p.m.Location: Poster Section 24Poster Board Number: 1 Abstract Number:\u00a0CT133 Title:\u00a0Trial … Continue reading \"UPDATE — Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-16T11:33:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTUxMiM1NDY1MjMxIzIyMDc3NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"UPDATE — Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023","datePublished":"2023-03-16T11:33:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/"},"wordCount":422,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTUxMiM1NDY1MjMxIzIyMDc3NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/","name":"UPDATE - Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTUxMiM1NDY1MjMxIzIyMDc3NDc=","datePublished":"2023-03-16T11:33:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTUxMiM1NDY1MjMxIzIyMDc3NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTUxMiM1NDY1MjMxIzIyMDc3NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/update-werewolf-therapeutics-announces-upcoming-presentations-at-aacr-annual-meeting-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"UPDATE — Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740626"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740626\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}